EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.
TRAIL is a death receptor ligand that induces cell death preferentially in tumor cells. Recombinant soluble TRAIL, however, performs poorly as an anti-cancer therapeutic because oligomerization is required for potent biological activity. We previously generated a diabody format of tumor-targeted TRA...
Main Authors: | Yvonne Möller, Martin Siegemund, Sven Beyes, Ricarda Herr, Daniele Lecis, Domenico Delia, Roland Kontermann, Tilman Brummer, Klaus Pfizenmaier, Monilola A Olayioye |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4157814?pdf=render |
Similar Items
-
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
by: Shawn T. Beug, et al.
Published: (2017-02-01) -
Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms
by: Dae-Sun Kim, et al.
Published: (2017-08-01) -
Smac mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt's lymphoma cell lines
by: Annkathrin Koch, et al.
Published: (2021-05-01) -
Future Therapeutic Directions for Smac-Mimetics
by: Emma Morrish, et al.
Published: (2020-02-01) -
Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic.
by: Federica Cossu, et al.
Published: (2012-01-01)